Inhibrx 관리

관리 기준 확인 3/4

Inhibrx CEO는 Mark Lappe, Jan2010 에 임명되었습니다 의 임기는 14.33 년입니다. 총 연간 보상은 $ 2.80M, 24.1% 로 구성됩니다. 24.1% 급여 및 75.9% 보너스(회사 주식 및 옵션 포함). 는 $ 103.89M 가치에 해당하는 회사 주식의 5.81% 직접 소유합니다. 103.89M. 경영진과 이사회의 평균 재임 기간은 각각 3.3 년과 3.3 년입니다.

주요 정보

Mark Lappe

최고 경영자

US$2.8m

총 보상

CEO 급여 비율	24.1%
CEO 임기	14.3yrs
CEO 소유권	5.8%
경영진 평균 재임 기간	3.3yrs
이사회 평균 재임 기간	3.3yrs

최근 관리 업데이트

Recent updates

Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Mar 23

CEO 보상 분석

Mark Lappe 의 보수는 Inhibrx 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$271m
Dec 31 2023	US$3m	US$675k	-US$241m
Sep 30 2023	n/a	n/a	-US$189m
Jun 30 2023	n/a	n/a	-US$172m
Mar 31 2023	n/a	n/a	-US$163m
Dec 31 2022	US$1m	US$650k	-US$145m
Sep 30 2022	n/a	n/a	-US$125m
Jun 30 2022	n/a	n/a	-US$111m
Mar 31 2022	n/a	n/a	-US$94m
Dec 31 2021	US$5m	US$650k	-US$82m
Sep 30 2021	n/a	n/a	-US$78m
Jun 30 2021	n/a	n/a	-US$78m
Mar 31 2021	n/a	n/a	-US$75m
Dec 31 2020	US$869k	US$530k	-US$76m
Sep 30 2020	n/a	n/a	-US$75m
Jun 30 2020	n/a	n/a	-US$74m
Mar 31 2020	n/a	n/a	-US$68m
Dec 31 2019	US$864k	US$450k	-US$51m

보상 대 시장: Mark 의 총 보상 ($USD 2.80M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 5.64M ).

보상과 수익: 회사가 수익성이 없는 동안 Mark 의 보상이 증가했습니다.

CEO

Mark Lappe (56 yo)

14.3yrs

테뉴어

US$2,802,021

보상

Mr. Mark Paul Lappe is Co-founded Inhibrx LLC in 2010. Mr. Lappe co-founded Efficacy Capital Limited in 2004 serves as its President and Managing Partner. Mr. Lappe co-founded Inhibrx in 2010 and serves as...

리더십 팀

이름	위치	테뉴어	보상	소유권
Mark Lappe	Founder	14.3yrs	US$2.80m	5.81% $ 103.9m
Brendan Eckelman	Founder & Chief Scientific Officer	14.1yrs	US$1.45m	4.5% $ 80.3m
Kelly Deck	Executive VP & CFO	4.1yrs	US$1.15m	0% $ 0
Quinn Deveraux	Founder	no data	데이터 없음	데이터 없음
Ashraf Amanullah	Executive VP & Chief Technical Operations Officer	no data	데이터 없음	데이터 없음
Leah Pollema	VP, Corporate Secretary & General Counsel	no data	데이터 없음	데이터 없음
Charbel Helaihel	Vice President of Marketing & Commercial Planning	1.3yrs	데이터 없음	데이터 없음
Jeffrey Jensen	Executive VP & Chief Clinical Operations Officer	4.3yrs	데이터 없음	데이터 없음
David Matly	Executive VP and Chief Commercial & Business Development Officer	2.6yrs	데이터 없음	데이터 없음
Carlos Bais	Executive Vice President of Translational Sciences	2yrs	데이터 없음	데이터 없음
Josep Garcia	EVP & Chief Clinical Development Officer	1.1yrs	데이터 없음	데이터 없음

3.3yrs

평균 재임 기간

49.5yo

평균 연령

경험이 풍부한 관리: INBX 의 관리팀은 경험 ( 3.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Mark Lappe	Founder	14.3yrs	US$2.80m	5.81% $ 103.9m
Stephen Howell	Member of Advisory Board	no data	데이터 없음	데이터 없음
Rand Mulford	Member of Advisory Board	no data	데이터 없음	데이터 없음
Douglas Forsyth	Independent Director	6.1yrs	US$317.03k	1.14% $ 20.4m
Kimberly Manhard	Independent Director	3.9yrs	US$298.03k	0% $ 0
John Kayyem	Independent Director	6.1yrs	US$306.53k	6.25% $ 111.7m
Victor Nizet	Member of Advisory Board	no data	데이터 없음	데이터 없음
Guy Salvesen	Scientific Advisor	no data	데이터 없음	데이터 없음
Kristiina Vuori	Independent Director	2.6yrs	US$300.53k	0% $ 0
Igor Barjaktarevic	Member of INBRX-101 Scientific Advisory Board	2.1yrs	데이터 없음	데이터 없음
Mark Brantly	Member of INBRX-101 Scientific Advisory Board	2.1yrs	데이터 없음	데이터 없음
Kenneth Chapman	Member of INBRX-101 Scientific Advisory Board	2.1yrs	데이터 없음	데이터 없음

3.3yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: INBX 의 이사회는 경험(평균 재직 기간 3.3 년)으로 간주됩니다.

Inhibrx 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Executive VP & CFO notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

High number of new and inexperienced directors

Recent updates

Inhibrx Files Form 15

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Aventis Inc. completed the acquisition of Inhibrx, Inc. (NasdaqGM:INBX) from a group of shareholders.

Inhibrx, Inc.(NasdaqGM:INBX) dropped from NASDAQ Biotechnology Index

Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc

Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc

Is Inhibrx (NASDAQ:INBX) Using Debt Sensibly?

First quarter 2024 earnings released: US$1.44 loss per share (vs US$1.12 loss in 1Q 2023)

Executive VP & CFO notifies of intention to sell stock

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Price target decreased by 20% to US$35.50

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Consensus revenue estimates decrease by 22%, EPS upgraded

Consensus revenue estimates increase by 308%, EPS downgraded

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$1.10 loss per share (vs US$0.90 loss in 3Q 2022)

Inhibrx, Inc. Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Inhibrx, Inc. announced that it has received $200.000633 million in funding

Inhibrx, Inc. announced that it expects to receive $199.999961 million in funding

Consensus revenue estimates increase by 26%

New major risk - Negative shareholders equity

Second quarter 2023 earnings released: US$1.08 loss per share (vs US$0.97 loss in 2Q 2022)

Inhibrx, Inc. Grants Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 85%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Consensus forecasts updated

Inhibrx, Inc. Updates Efficacy and Safety Data from Ongoing Phase 1 INBRX-109 Expansion Cohorts for the Treatment of Chondrosarcoma

Consensus revenue estimates increase by 42%

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

Inhibrx down 8% after announcing webcast for pathway for rare disease candidate

Founder & Chief Scientific Officer notifies of intention to sell stock

Consensus revenue estimates fall by 22%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Founder & Chief Scientific Officer notifies of intention to sell stock

Inhibrx, Inc. Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105

Inhibrx: Potential To Move To Registration Study With INBRX-101

High number of new and inexperienced directors

INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing

Consensus revenue estimates fall by 17%

Inhibrx, Inc. to Host Webcast Presentation of Topline Results from the Phase 1 Trial of INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Price target decreased to US$49.67

Inhibrx, Inc. Announces Formation of A Scientific Advisory Board for Its INBRX-101 program

Inhibrx, Inc., Annual General Meeting, May 25, 2022

Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Price target decreased to US$49.67

Consensus forecasts updated

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Inhibrx, Inc. Announces Initial Phase 1 Dose Escalation Results for INBRX-106

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.77 loss in 3Q 2020)

Price target increased to US$42.60

Second quarter 2021 earnings released: US$0.55 loss per share (vs US$0.98 loss in 2Q 2020)

Inhibrx, Inc.(NasdaqGM:INBX) dropped from Russell 3000E Value Index

CEO 보상 분석

CEO

테뉴어